A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report

Overview of attention for article published in OncoTargets and therapy, April 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 257 followers.

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report https://t.co/8FgNddflES

29 Apr 2021

Reply Repost Favourite

Dove Medical Press

Article Metrics

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report

Mentioned by

Citations

Readers on